论文部分内容阅读
为探讨PC、PS在恶性肿瘤诊治中的应用价值，本文测定了92例恶性肿瘤患者的PC、PS抗凝活性。结果：PC：A以肺癌组为最高；肝癌组最低，与正常对照组比较P均＜0.01。其他癌症组与正常组比较P＞0．05。PS：A除肝癌组低于正常对照组外（P＜0．05），其余癌症组与正常组比较P均＞0．05。17例恶性肿瘤经治疗后PC：A高于治疗前（P＜0．05）；而PS：A治疗前后比较无显著差异（P＞0．05）。经手术治疗病人的PC：A，以术后1周内为最低，术后2周恢复正常水平。结论：血浆PC:A检测可作为肺癌、肝癌等的辅助诊断指标，如连续测定PC：A的动态变化有助于判断疗效及预测预后。
In order to explore the application value of PC and PS in the diagnosis and treatment of malignant tumors, the anticoagulant activity of PC and PS was determined in 92 patients with malignant tumors. Results: PC: A was the highest in the lung cancer group; the liver cancer group was the lowest, and P <0.01 compared with the normal control group. Other cancer groups were compared with normal group P>0.05. PS:A with the exception of the liver cancer group was lower than the normal control group (P<0.05), the other cancer groups compared with the normal group P>0.05. After treatment of 17 malignant tumors PC:A was higher than before treatment (P <0.05); There was no significant difference between PS and A before and after treatment (P>0.05). The patient’s PC:A after surgery was lowest in 1 week after operation, and returned to normal level 2 weeks after operation. Conclusion: The detection of plasma PC:A can be used as an auxiliary diagnostic index for lung cancer, liver cancer, etc. The continuous measurement of PC:A dynamic changes can help determine the efficacy and predict prognosis.